A recent study suggests that GLP-1 receptor agonists (GLP-1RAs) may lower the risk of hematologic cancers, including leukemia ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

MONDAY, March 3, 2025 (HealthDay News) — Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonist use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use.

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce inflammation and improve heart health. With such advantages, the demand ...

Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

Stopping GLP-1 receptor agonists 14 days prior to total hip or knee arthroplasty may reduce several key risk factors ...

No significant differences were seen in the odds of postoperative pneumonia between GLP-1 RA users and nonusers in an adjusted analysis (odds ratio, 0.78; 95% confidence interval, 0.57 to 1.06; P ...

When Jenni* started using a medication called liraglutide to lose weight, she noticed changes not just in her appetite, but in how she thought about food. Where the smell of hot chips in the deep ...

However, for crude incidence rates there was an increased incidence of suicidality with GLP-1 receptor agonist vs DPP-4 inhibitor use; 3.9 vs 1.8 per 1000 person-years. HealthDay News — Glucagon ...

HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared ...